Pfizer

Why is Pfizer Ltd. falling/rising?

As of 17-Jun, Pfizer Ltd. is experiencing a decline in its stock price, currently at 4,500.95, with a year-to-date drop of 9.66% and a significant 23.20% decrease over the past year. The stock is underperforming against market benchmarks and shows bearish trends, compounded by declining investor interest and concerns over long-term growth prospects.

As of 17-Jun, Pfizer Ltd. is experiencing a slight decline in its stock price, currently at 4,500.95, which reflects a change of -1.45 (-0.03%). The stock has shown poor performance over various time frames, with a year-to-date decline of 9.66% and a significant drop of 23.20% over the past year. This underperformance is further highlighted by its negative returns over the past week and month, where it has decreased by 0.82% and 8.87%, respectively, while the benchmark Sensex has risen by 4.29% and 2.55% in the same periods.<BR><BR>The stock is also trading lower than its moving averages across all time frames, indicating a bearish trend. Additionally, there has been a decrease in investor participation, with delivery volume falling by 3.65% against the 5-day average. Although the company boasts a high dividend yield of 3.65%, this has not been enough to offset the concerns regarding its long-term growth prospects, as evidenced by a modest annual growth rate in net sales of 2.39% and operating profit of 7.03% over the last five years.<BR><BR>Moreover, the stock is trading at a high price-to-book value of 4.9, suggesting it may be overvalued compared to its peers. Despite a rise in profits by 19.8% over the past year, the stock's negative return of -23.20% indicates that market sentiment remains weak. Overall, the combination of poor long-term growth, declining investor interest, and unfavorable comparisons to market benchmarks contributes to the falling stock price of Pfizer Ltd.

Which are the latest news on Pfizer?

What does Pfizer do?

Pfizer Limited is a Small Cap pharmaceutical company in India, involved in manufacturing and marketing drugs, with recent net sales of 629 Cr and a net profit of 200 Cr as of March 2026. Key metrics include a P/E ratio of 27.00 and a dividend yield of 3.64%.

Overview:<BR>Pfizer Limited is engaged in the manufacturing, marketing, trading, and export of pharmaceutical products within the Pharmaceuticals & Biotechnology industry and is categorized as a Small Cap company.<BR><BR>History:<BR>Pfizer Limited has established itself as a pioneer in clinical research in India. The latest quarterly results reported are for March 2026, showcasing the company's ongoing operations.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 629 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 200 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 20,907 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 27.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 3.64% <BR>Debt-Equity: -0.72 <BR>Return on Equity: 18.05% <BR>Price to Book: 4.94 <BR><BR>Contact Details:<BR>Address: The Capital 1802/1901 Plot-C70, G Bl Bandra Kurla Cpx Bandra-E Mumbai Maharashtra : 400051 <BR>Phone: 91-22-66932000 <BR>Email: contactus.india@pfizer.com <BR>Website: http://www.pfizerindia.com

How big is Pfizer?

Summary could not be generated.

As of 10th June, Pfizer Ltd. has a market capitalization of 20,907.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, Pfizer reported net sales of 2,519.65 Cr and a net profit of 722.43 Cr.<BR><BR>The reporting period for the balance sheet data is the latest annual period, but specific values for Shareholder's Funds and Total Assets are unavailable.

Who are in the management team of Pfizer?

The management team of Pfizer includes Prajeet Nair (Company Secretary), Uday Khanna and Sunil Lalbhai (Independent Directors), Milind Anil Patil (Executive Director, Finance), Meena Ganesh (Independent Director), Samir Kazi (Executive Director), Pradip P Shah (Chairman, Independent Director), and Meenakshi Nevatia (Managing Director), who collectively guide the company's strategic direction and ensure regulatory compliance.

The management team of Pfizer includes the following individuals:<BR><BR>- **Prajeet Nair**: Company Secretary & Compliance Officer<BR>- **Uday Khanna**: Independent Director<BR>- **Sunil Lalbhai**: Independent Director<BR>- **Milind Anil Patil**: Executive Director (Finance)<BR>- **Meena Ganesh**: Independent Director<BR>- **Samir Kazi**: Executive Director<BR>- **Pradip P Shah**: Chairman & Independent Director<BR>- **Meenakshi Nevatia**: Managing Director<BR><BR>This team plays a crucial role in guiding the company's strategic direction and ensuring compliance with regulatory standards.

Who are the peers of the Pfizer?

Pfizer's peers include Acutaas Chemical, Sai Life, Piramal Pharma, Neuland Labs, AstraZeneca, ERIS Lifescience, Granules India, OneSource Specialty, and Caplin Point Lab. Acutaas Chemical shows the highest 1-year return at 187.22%, while Pfizer's return is -22.16%.

Peers: The peers of Pfizer are Acutaas Chemical, Sai Life, Piramal Pharma, Neuland Labs., Astrazeneca Phar, ERIS Lifescience, Granules India, OneSource Speci., and Caplin Point Lab.<BR><BR>Quality Snapshot: Excellent management risk is observed at Acutaas Chemical and Astrazeneca Phar, while Good management risk is found at Neuland Labs., ERIS Lifescience, Granules India, and Caplin Point Lab. Average management risk is present at Sai Life and Piramal Pharma, and Below Average management risk is noted at OneSource Speci. For Growth, Excellent growth is seen at Acutaas Chemical and Sai Life, while Good growth is found at Neuland Labs. and Piramal Pharma. Below Average growth is noted at Pfizer, ERIS Lifescience, Granules India, and Caplin Point Lab, and the rest have Average growth. In terms of Capital Structure, Excellent capital structure is observed at Acutaas Chemical, Neuland Labs., Astrazeneca Phar, Granules India, and Caplin Point Lab, while Good capital structure is found at ERIS Lifescience, and Below Average capital structure is noted at Piramal Pharma and OneSource Speci.<BR><BR>Return Snapshot: Acutaas Chemical has the highest 1-year return at 187.22%, while Piramal Pharma has the lowest at -19.61%. Pfizer's 1-year return is -22.16%, which is lower than Piramal Pharma's. Additionally, the peers with negative six-month returns include Piramal Pharma and ERIS Lifescience.

Are Pfizer Ltd. latest results good or bad?

Pfizer Ltd.'s latest results show a mixed performance: while net profit increased 40.89% sequentially to ₹199.82 crore, it declined 39.61% year-on-year. Revenue rose 6.31% year-on-year but fell 2.45% sequentially, indicating potential challenges in sustaining growth amidst a competitive market.

Pfizer Ltd.'s latest results present a mixed picture. In the fourth quarter of FY26, the company reported a net profit of ₹199.82 crore, which is a significant sequential increase of 40.89% compared to the previous quarter. However, this figure reflects a concerning year-on-year decline of 39.61%. <BR><BR>Revenue for the same quarter was ₹629.23 crore, showing a slight decline of 2.45% from the previous quarter but an increase of 6.31% compared to the same quarter last year. While the year-on-year growth in revenue is a positive sign, the sequential dip raises questions about the sustainability of this growth.<BR><BR>The operating margin improved to 37.50%, up 2.12 percentage points from the previous quarter, indicating better operational efficiency. However, the profit after tax margin fell significantly from the previous year, highlighting some challenges in maintaining profitability.<BR><BR>Overall, while there are positive aspects such as improved sequential profit and operating margins, the year-on-year declines in net profit and the slight revenue drop indicate underlying weaknesses that need to be addressed. The company’s growth trajectory appears to be a concern, especially in a competitive pharmaceutical landscape.

Should I buy, sell or hold Pfizer Ltd.?

When is the next results date for Pfizer Ltd.?

The next results date for Pfizer Ltd. is 12 May 2026.

The next results date for Pfizer Ltd. is scheduled for 12 May 2026.

Is Pfizer technically bullish or bearish?

As of December 1, 2025, Pfizer's technical stance is mildly bearish due to bearish MACD, Bollinger Bands, and KST indicators on weekly and monthly charts, despite a mildly bullish signal from daily moving averages.

As of 1 December 2025, the technical trend has changed from mildly bullish to mildly bearish. The current technical stance for Pfizer is mildly bearish. Key indicators driving this stance include a bearish MACD on both weekly and monthly time frames, bearish Bollinger Bands across both time frames, and a bearish KST on the weekly chart. The daily moving averages show a mildly bullish signal, but this is overshadowed by the overall bearish sentiment in the weekly and monthly indicators. Additionally, the stock has underperformed compared to the Sensex across multiple time frames, further supporting the bearish outlook.

How has been the historical performance of Pfizer?

Pfizer's historical performance shows fluctuating net sales, increasing from 681.70 Cr in 2008 to 772.27 Cr in 2009, but profitability declined, with profit after tax dropping from 299.58 Cr to 137.12 Cr due to rising expenditures. Despite sales growth, the company faced challenges in managing costs, leading to reduced profit margins.

Answer:<BR>The historical performance of Pfizer shows a trend of fluctuating net sales and profits over the years reported.<BR><BR>Breakdown:<BR>Pfizer's net sales increased from 681.70 Cr in November 2008 to 772.27 Cr in November 2009, indicating a positive growth trend. Other operating income also rose slightly from 22.90 Cr in November 2008 to 24.37 Cr in November 2009. Total operating income followed this upward trajectory, reaching 796.64 Cr in November 2009, up from 704.60 Cr the previous year. However, total expenditure increased significantly from 552.36 Cr in November 2008 to 638.47 Cr in November 2009, leading to an operating profit (PBDIT) of 229.22 Cr in November 2009, which was a modest increase from 222.35 Cr in November 2008. The profit before tax saw a notable decline from 419.13 Cr in November 2008 to 210.01 Cr in November 2009, and consequently, profit after tax also decreased from 299.58 Cr to 137.12 Cr in the same period. This resulted in a drop in earnings per share from 100.4 to 45.95. The operating profit margin and profit after tax margin also decreased, reflecting a decline in profitability. Overall, while Pfizer experienced growth in sales, the profitability metrics suggest challenges in managing costs effectively during this period.

Who are the top shareholders of the Pfizer?

The top shareholders of Pfizer include Pfizer East India B V with 39.75%, mutual funds holding 11.59%, individual investors at 12.34%, and Nippon Life India Trustee Ltd as the largest public shareholder with 4.17%. Foreign Institutional Investors (FIIs) hold 2.18% of the shares.

The top shareholders of Pfizer include Pfizer East India B V, which holds the largest share at 39.75%. Other significant shareholders include mutual funds, which collectively hold 11.59% through 24 schemes, and individual investors, who account for 12.34% of the shares. Additionally, Nippon Life India Trustee Ltd is the highest public shareholder with a 4.17% stake. Foreign Institutional Investors (FIIs) hold 2.18% of the shares through 67 different entities.

Is Pfizer overvalued or undervalued?

As of December 12, 2023, Pfizer is considered very expensive and overvalued with a PE ratio of 41.15 and an EV to EBITDA of 32.17, significantly higher than peers like Sun Pharma and Cipla, despite outperforming the Sensex in the short term.

As of 12 December 2023, Pfizer's valuation grade has moved from expensive to very expensive, indicating a significant increase in perceived valuation. The company is currently considered overvalued. Key ratios include a PE ratio of 41.15, an EV to EBITDA of 32.17, and a PEG ratio of 2.56, all of which are substantially higher than many of its peers.<BR><BR>In comparison, Sun Pharma has a PE ratio of 35.25 and an EV to EBITDA of 24.91, while Cipla stands at a much lower PE of 22.99 and an EV to EBITDA of 15.93, showcasing that Pfizer's valuation metrics are considerably elevated. Additionally, Pfizer's recent stock performance has outpaced the Sensex over the past month and year, with returns of 32.93% and 14.79%, respectively, although it still lags behind the Sensex over longer periods.

Has Pfizer declared dividend?

Yes, Pfizer has declared a dividend of 350%, amounting to 35 per share, with an ex-date of August 21, 2024. The dividend yield is 0.6%, and total returns over various periods have shown positive performance, particularly in the long term.

Pfizer Ltd. has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 350%<BR>- Amount per share: 35<BR>- Ex-date: 21 Aug 24<BR><BR>Dividend Yield: 0.6%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 9.39%, with no dividend return, resulting in a total return of 9.39%.<BR><BR>Over the past year, the price return was 17.0%, with a dividend return of 0.71%, leading to a total return of 17.71%.<BR><BR>In the 2-year period, the price return was 44.62%, with a dividend return of 1.04%, culminating in a total return of 45.66%.<BR><BR>For the 3-year period, the price return was 36.06%, with a dividend return of 2.55%, resulting in a total return of 38.61%.<BR><BR>In the 4-year period, the price return was 10.34%, with a dividend return of 1.97%, leading to a total return of 12.31%.<BR><BR>Over the last 5 years, the price return was 39.69%, with a dividend return of 2.87%, resulting in a total return of 42.56%.<BR><BR>Overall, Pfizer's recent dividend declaration reflects a significant return to shareholders, and the total returns over various periods indicate a generally positive performance, particularly in the longer term.